Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaskin Peanut Long-term Follow-up (PEOPLE)
NCT03013517Phase 3Unknown
- Sponsor
- DBV Technologies
- Start
- Jan 2017
- Primary completion
- Nov 2019
- Modality
- Transdermal Patches
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Primary endpoint: Percentage of subjects originating from the active arm of PEPITES reaching an Eliciting Dose (ED) ≥ 1,000 mg at Month 24. Status: unknown.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03013517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013517.